NCT01606358

Brief Summary

In patients with an ovarian cancer, the treatment is currently based on surgery and chemotherapy. The impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated. The long term goal is to give a rational to combine conventional treatment of ovarian cancer with immunotherapy based on Vgamma9Vdelta2 T cells.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 25, 2012

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Last Updated

August 11, 2014

Status Verified

August 1, 2014

First QC Date

May 23, 2012

Last Update Submit

August 8, 2014

Conditions

Ovarian Cancer

Keywords

Ovarian CancerPatient with ovarian cancer

Study Arms (1)

Ovarian Cancer

Drug: Carboplatin and / or taxol chemotherapy

Interventions

Carboplatin and / or taxol chemotherapyDRUG

Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).

Ovarian Cancer

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy.

You may qualify if:

  • Patients with proven epithelial ovarian cancer
  • Patients receiving carboplatin and / or taxol chemotherapy.

You may not qualify if:

  • Minor patient
  • Protected adult
  • Lack of invasion to the final histological checking
  • Absence of chemotherapy in the therapeutic plan of treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de RENNES

Rennes, 35000, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

The VGAMMA9VDELTA2 T cells will be isolated from peripheral blood mononuclear cells of patients with ovarian cancer.

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Carboplatin

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Intervention Hierarchy (Ancestors)

Coordination ComplexesOrganic Chemicals

Study Officials

  • Bruno Laviolle, MD PhD

    Rennes University Hospital

    STUDY CHAIR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 23, 2012

First Posted

May 25, 2012

Primary Completion

May 1, 2016

Last Updated

August 11, 2014

Record last verified: 2014-08

Locations

FR(1)